{"id":7250,"date":"2021-07-26T18:14:50","date_gmt":"2021-07-27T01:14:50","guid":{"rendered":"https:\/\/www.bluerocktx.com\/?p=7250"},"modified":"2023-06-26T14:31:33","modified_gmt":"2023-06-26T18:31:33","slug":"bluerock-therapeutics-announces-new-board-chair-new-president-and-ceo","status":"publish","type":"post","link":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-announces-new-board-chair-new-president-and-ceo\/","title":{"rendered":"BlueRock Therapeutics Announces New Board Chair, New President and CEO"},"content":{"rendered":"<p><strong>CAMBRIDGE, Mass., July 26, 2021<\/strong> \u2014 BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer\u202fAG, announced\u202ftoday\u202fthat Emile Nuwaysir, Ph.D., current President and CEO, will transition to the position of BlueRock Board Chair, effective August 1, 2021. Current Chief Scientific Officer Seth Ettenberg, Ph.D., will assume the role of President and CEO. BlueRock will continue in its mission to create authentic cellular medicines to reverse devastating diseases and improve the human condition.<\/p>\n<p>Under Dr. Nuwaysir\u2019s leadership since 2017, BlueRock has grown from a small, pre-clinical startup to a clinical-stage company with over 200 employees in two countries. BlueRock also recently initiated a first-of-its-kind trial of pluripotent stem-cell derived dopaminergic neurons in patients with advanced Parkinson\u2019s disease. In his new role, Dr. Nuwaysir will continue to take an active role in the growth and maturation of BlueRock, providing guidance and support on both corporate strategy and R&amp;D.<\/p>\n<p>\u201cIt is an incredibly exciting time at BlueRock, as our Parkinson\u2019s program advances in the clinic and our research pipeline and strategic partnerships continue to accelerate. I\u2019m deeply grateful for the opportunity over the past five years to lead this world-class BlueRock team, and to partner with Bayer to realize our potential.\u202fIn my new role as Board Chair, I look forward to working with Seth to bring our revolutionary new medicines to the patients who desperately need them.\u201d<\/p>\n<p>\u201cEmile\u2019s leadership has been a key driving force in BlueRock\u2019s growth. We are very grateful for his contributions and pleased that he will continue to work closely with us in his new role as Board Chair,\u201d said Stefan Oelrich, Member of the Board of Management, Bayer and President of the Bayer\u2019s Pharmaceuticals Division. \u201cWith Seth as the new CEO, I am certain BlueRock will continue to thrive and advance in its mission to bring revolutionary treatments to patients. We are excited about the future ahead and look forward to working with Seth.\u201d<\/p>\n<p>Since joining BlueRock in 2020, Dr. Ettenberg has been an exceptional leader of the Research organization, helping to shape the pipeline and advance BlueRock\u2019s proprietary cell+gene platform. To aid in the transition to BlueRock\u2019s next phase of growth, Dr. Ettenberg has experience building a small biotech as well as a deep understanding of how to work and thrive within a large pharmaceutical ecosystem. An accomplished discovery scientist with a true entrepreneurial spirit, Dr. Ettenberg has brought several novel cellular therapies from invention to clinical testing, a critical skill as the BlueRock pipeline matures.<\/p>\n<p>\u201cWe have begun our journey to change medicine and to address some of the most devastating degenerative diseases, where currently we can only offer a slowed trajectory of deterioration,\u201d states Dr. Ettenberg. \u201cOur mission is to create a living medicine that can address the complex nature of these diseases, and in turn, create hope not just for treatment of symptoms, but for a cure. I cannot imagine a more exciting time to lead BlueRock.\u201d<\/p>\n<p><strong>About BlueRock Therapeutics<\/strong><\/p>\n<p>BlueRock Therapeutics is an engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. The company\u2019s cell+gene platform enables the creation, manufacture, and delivery of authentic cell therapies with engineered functionality by simultaneously harnessing pluripotent cell biology and genome editing. This enables an approach where, in theory, any cell in the body can be manufactured and any gene in the genome can be engineered for therapeutic purposes. The platform is broadly applicable, but the company is focused today in neurology, cardiology, immunology, and ophthalmology. In August 2019, the company was acquired by Bayer AG, for an enterprise value of $1B in upfront and milestone payments. For BlueRock this marks the next step in the journey to prove degenerative disease is reversible, and to bring our revolutionary new medicines to the patients who desperately need them. For more information, visit <a href=\"http:\/\/bluerocktx.com\/\"><span class=\"s1\">bluerocktx.com<\/span><\/a>.<\/p>\n<p><strong>About Bayer<\/strong><\/p>\n<p>Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to\u202fhelp\u202fpeople\u202fand planet thrive\u202fby supporting efforts to\u202fmaster\u202fthe major challenges presented by a growing and aging global population.\u202fBayer is committed to drive sustainable development and generate a positive impact with its businesses.\u202fAt the same time, the Group aims to increase its earning power and create value through innovation and growth.\u202fThe\u202fBayer brand stands for trust, reliability,\u202fand quality throughout the world. In fiscal\u202f2020, the Group employed around\u202f100,000 people and had sales of\u202f41.4\u202fbillion euros.\u202fR&amp;D expenses before special items\u202famounted to\u202f4.9 billion euros.\u202fFor more information,\u202fgo to\u202f<a href=\"http:\/\/www.bayer.com\/\" target=\"_blank\" rel=\"noopener\"><span class=\"s1\">www.bayer.com<\/span><\/a>.<\/p>\n<p><strong>Forward-Looking Statements<\/strong><\/p>\n<p>Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201cforecast,\u201d \u201cestimate\u201d and \u201cintend,\u201d among others. These forward-looking statements are based on BlueRock\u2019s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the timing of our any clinical trials our product candidates; our results regarding the safety, tolerance and efficacy of our product candidates; and ongoing FDA and other regulatory requirements regarding the development of our product candidates. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Except as expressly required by law, BlueRock does not undertake an obligation to update or revise any forward-looking statement. All of the Company\u2019s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., July 26, 2021 \u2014 BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer\u202fAG, announced\u202ftoday\u202fthat Emile Nuwaysir, Ph.D., current President and CEO, will transition to the position of BlueRock Board Chair, effective August 1, 2021. Current Chief Scientific Officer Seth [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":7708,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[45],"tags":[54],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>BlueRock Therapeutics Announces New Board Chair, New President and CEO - BlueRock Therapeutics LP<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-announces-new-board-chair-new-president-and-ceo\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BlueRock Therapeutics Announces New Board Chair, New President and CEO - BlueRock Therapeutics LP\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., July 26, 2021 \u2014 BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer\u202fAG, announced\u202ftoday\u202fthat Emile Nuwaysir, Ph.D., current President and CEO, will transition to the position of BlueRock Board Chair, effective August 1, 2021. Current Chief Scientific Officer Seth [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-announces-new-board-chair-new-president-and-ceo\/\" \/>\n<meta property=\"og:site_name\" content=\"BlueRock Therapeutics LP\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-27T01:14:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-26T18:31:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2023\/06\/BR-Logo-Card.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"1000\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"BlueRock Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"BlueRock Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-announces-new-board-chair-new-president-and-ceo\/\",\"url\":\"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-announces-new-board-chair-new-president-and-ceo\/\",\"name\":\"BlueRock Therapeutics Announces New Board Chair, New President and CEO - BlueRock Therapeutics LP\",\"isPartOf\":{\"@id\":\"https:\/\/www.bluerocktx.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-announces-new-board-chair-new-president-and-ceo\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-announces-new-board-chair-new-president-and-ceo\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2023\/06\/BR-Logo-Card.jpg\",\"datePublished\":\"2021-07-27T01:14:50+00:00\",\"dateModified\":\"2023-06-26T18:31:33+00:00\",\"author\":{\"@id\":\"https:\/\/www.bluerocktx.com\/#\/schema\/person\/7bce67a9ee8dcf888329288a28761057\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-announces-new-board-chair-new-president-and-ceo\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-announces-new-board-chair-new-president-and-ceo\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-announces-new-board-chair-new-president-and-ceo\/#primaryimage\",\"url\":\"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2023\/06\/BR-Logo-Card.jpg\",\"contentUrl\":\"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2023\/06\/BR-Logo-Card.jpg\",\"width\":900,\"height\":1000,\"caption\":\"BlueRock Therapeutics Logo Card\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-announces-new-board-chair-new-president-and-ceo\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.bluerocktx.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BlueRock Therapeutics Announces New Board Chair, New President and CEO\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.bluerocktx.com\/#website\",\"url\":\"https:\/\/www.bluerocktx.com\/\",\"name\":\"BlueRock Therapeutics LP\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.bluerocktx.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.bluerocktx.com\/#\/schema\/person\/7bce67a9ee8dcf888329288a28761057\",\"name\":\"BlueRock Therapeutics\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.bluerocktx.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/154b53ac9f1feafa6f14d0efa17a4fdb?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/154b53ac9f1feafa6f14d0efa17a4fdb?s=96&d=mm&r=g\",\"caption\":\"BlueRock Therapeutics\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BlueRock Therapeutics Announces New Board Chair, New President and CEO - BlueRock Therapeutics LP","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-announces-new-board-chair-new-president-and-ceo\/","og_locale":"en_US","og_type":"article","og_title":"BlueRock Therapeutics Announces New Board Chair, New President and CEO - BlueRock Therapeutics LP","og_description":"CAMBRIDGE, Mass., July 26, 2021 \u2014 BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer\u202fAG, announced\u202ftoday\u202fthat Emile Nuwaysir, Ph.D., current President and CEO, will transition to the position of BlueRock Board Chair, effective August 1, 2021. Current Chief Scientific Officer Seth [&hellip;]","og_url":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-announces-new-board-chair-new-president-and-ceo\/","og_site_name":"BlueRock Therapeutics LP","article_published_time":"2021-07-27T01:14:50+00:00","article_modified_time":"2023-06-26T18:31:33+00:00","og_image":[{"width":900,"height":1000,"url":"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2023\/06\/BR-Logo-Card.jpg","type":"image\/jpeg"}],"author":"BlueRock Therapeutics","twitter_card":"summary_large_image","twitter_misc":{"Written by":"BlueRock Therapeutics","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-announces-new-board-chair-new-president-and-ceo\/","url":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-announces-new-board-chair-new-president-and-ceo\/","name":"BlueRock Therapeutics Announces New Board Chair, New President and CEO - BlueRock Therapeutics LP","isPartOf":{"@id":"https:\/\/www.bluerocktx.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-announces-new-board-chair-new-president-and-ceo\/#primaryimage"},"image":{"@id":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-announces-new-board-chair-new-president-and-ceo\/#primaryimage"},"thumbnailUrl":"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2023\/06\/BR-Logo-Card.jpg","datePublished":"2021-07-27T01:14:50+00:00","dateModified":"2023-06-26T18:31:33+00:00","author":{"@id":"https:\/\/www.bluerocktx.com\/#\/schema\/person\/7bce67a9ee8dcf888329288a28761057"},"breadcrumb":{"@id":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-announces-new-board-chair-new-president-and-ceo\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.bluerocktx.com\/bluerock-therapeutics-announces-new-board-chair-new-president-and-ceo\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-announces-new-board-chair-new-president-and-ceo\/#primaryimage","url":"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2023\/06\/BR-Logo-Card.jpg","contentUrl":"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2023\/06\/BR-Logo-Card.jpg","width":900,"height":1000,"caption":"BlueRock Therapeutics Logo Card"},{"@type":"BreadcrumbList","@id":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-announces-new-board-chair-new-president-and-ceo\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.bluerocktx.com\/"},{"@type":"ListItem","position":2,"name":"BlueRock Therapeutics Announces New Board Chair, New President and CEO"}]},{"@type":"WebSite","@id":"https:\/\/www.bluerocktx.com\/#website","url":"https:\/\/www.bluerocktx.com\/","name":"BlueRock Therapeutics LP","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.bluerocktx.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.bluerocktx.com\/#\/schema\/person\/7bce67a9ee8dcf888329288a28761057","name":"BlueRock Therapeutics","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.bluerocktx.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/154b53ac9f1feafa6f14d0efa17a4fdb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/154b53ac9f1feafa6f14d0efa17a4fdb?s=96&d=mm&r=g","caption":"BlueRock Therapeutics"}}]}},"_links":{"self":[{"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/posts\/7250"}],"collection":[{"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/comments?post=7250"}],"version-history":[{"count":5,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/posts\/7250\/revisions"}],"predecessor-version":[{"id":7631,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/posts\/7250\/revisions\/7631"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/media\/7708"}],"wp:attachment":[{"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/media?parent=7250"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/categories?post=7250"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/tags?post=7250"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}